Effect of Buzhong Yiqi Tang on Cisplatin Resistance A549/DDP Cells in Nude Mice with Lung Adenocarcinoma

Ying ZHANG; Yuan GAO; Chun-ying LIU

doi:10.13422/j.cnki.syfjx.20191822

您当前的位置：

首页 >

文章列表页 >

Effect of Buzhong Yiqi Tang on Cisplatin Resistance A549/DDP Cells in Nude Mice with Lung Adenocarcinoma

Pharmacology | 更新时间：2021-02-09

- Effect of Buzhong Yiqi Tang on Cisplatin Resistance A549/DDP Cells in Nude Mice with Lung Adenocarcinoma
- Chinese Journal of Experimental Traditional Medical Formulae Vol. 25, Issue 23, Pages: 73-78(2019)
- 作者机构：
  
  辽宁中医药大学，沈阳　 110032
- 作者简介：
- 基金信息：
- DOI：10.13422/j.cnki.syfjx.20191822
  CLC： R22; R242; R2-031; R285.5
- Received：08 January 2019，
  
  Published Online：05 June 2019，
  
  Published：05 December 2019
- 稿件说明：
移动端阅览
Ying ZHANG, Yuan GAO, Chun-ying LIU. Effect of Buzhong Yiqi Tang on Cisplatin Resistance A549/DDP Cells in Nude Mice with Lung Adenocarcinoma[J]. Chinese journal of experimental traditional medical formulae, 2019, 25(23): 73-78.
DOI：

Ying ZHANG, Yuan GAO, Chun-ying LIU. Effect of Buzhong Yiqi Tang on Cisplatin Resistance A549/DDP Cells in Nude Mice with Lung Adenocarcinoma[J]. Chinese journal of experimental traditional medical formulae, 2019, 25(23): 73-78. DOI： 10.13422/j.cnki.syfjx.20191822.

摘要

目的：

探讨补中益气汤对肺腺癌荷瘤裸鼠肿瘤细胞A549/DDP顺铂耐药的影响，并确定最佳用药浓度。

方法：

36只BALB/C裸鼠随机分为空载组，模型组，顺铂组，补中益气汤低、中、高剂量(1.46，2.92，5.84 g·kg

－1

)组。空载组接种转化生长因子-

(transforming growth factor-

，TGF-

)空载慢病毒转染的A549/DDP细胞，余接种TGF-

稳定过表达的A549/DDP细胞。药物干预后处死裸鼠。称量小鼠瘤重，计算抑瘤率；镜下计数肿瘤肝、脾、肺转移情况；病理观察肺组织形态学改变；免疫组化、蛋白免疫印迹法(Western blot)，实时荧光定量聚合酶链式反应(Real-time PCR)检测移植瘤中肺耐药相关蛋白(lung resistance-related protein，LRP)，多药耐药相关蛋白(multidrug resistance-related protein，MRP)，P-糖蛋白(P-glycoprotein，P-gp)表达情况。

结果：

与模型组比较，补中益气汤组瘤重降低，肺转移结节数量减少，随着补中益气汤剂量增加，瘤重逐渐减小，抑瘤率上升，高剂量组效果最为明显(

0.05)。肝、脾未见明显转移结节。病理切片显示，模型组肺部结构紊乱，出现明显肺损伤，补中益气汤组肺泡、肺泡囊、肺间隔形态逐渐恢复，高剂量组效果最好。与空载组比较，模型组LRP，MRP，P-gp蛋白和mRNA表达均明显上调(

0.05)；与模型组和顺铂组比较，补中益气汤中、高剂量组LRP，MRP，P-gp蛋白和mRNA表达明显下调(

0.05)；高剂量组下调效果最为明显。

结论：

补中益气汤能抑制肺腺癌移植瘤生长及转移，减轻肺损伤，改善A549/DDP顺铂耐药，该作用有一定的量效关系，高剂量(5.84 g·kg

－1

)为最佳裸鼠体内用药浓度。

Abstract

Objective:

To investigate the effect of Buzhong Yiqi Tang on cisplatin resistance tumor cells A549/DDP in nude mice with lung adenocarcinoma

and determine the optimal concentration.

Method:

The 36 BALB/C nude mice were randomly divided into no-load group

model group

cisplatin group

low-dose Buzhong Yiqi Tang group (1.46 g·kg

-1

)

medium-dose Buzhong Yiqi Tang group (2.92 g·kg

-1

) and high-dose Buzhong Yiqi Tang group (5.84 g·kg

-1

). The no-load group was inoculated with A549/DDP cells transfected by uninfected lentiviral transforming growth factor-

(TGF-

)

and the other groups were inoculated with TGF-

over-expression A549/DDP cells. After the intervention

the nude mice were put to death. The tumors of mice were weighed

and the inhibition rate was calculated

liver

spleen and lung metastases of tumors were counted under microscope

and pathological observation was made for lung histomorphological changes. Immunohistochemistry

Western blot and Real-time polymerase chain reaction(Real-time PCR) were used to detect the expressions of lung resistance-related protein (LRP)

multidrug resistance-related protein (MRP)

P-glycoprotein (P-gp) in transplantation tumor.

Result:

Compared with the model group

the weight of tumors and the number of pulmonary metastatic nodules decreased in the Buzhong Yiqi Tang intervention group. With the increase of the dosage of Buzhong Yiqi Tang

the weight of tumors gradually decreased

while the inhibition rate increased. The effect of the high-dose group was the most significant (

0.05). No obvious metastatic nodule was found in liver and spleen. Pathological sections showed that the structure of lungs in the model group was disordered with obvious lung injury. The morphology of alveoli

alveolar sac and pulmonary septum gradually recovered in the Buzhong Yiqi Tang group

and the effect of the high-dose group was the most obvious. Compared with the no-load group

the expressions of LRP

MRP

P-gp protein and mRNA in the model group was up-regulated (

0.05). compared with the model group and the cisplatin group

the expressions of LRP

MRP

P-gp protein and mRNA in middle-dose and high-dose Buzhong Yiqi Tang groups were down-regulated significantly (

0.05)

effect of the high-dose group was the most significant.

Conclusion:

Buzhong Yiqi Tang can inhibit the growth and metastasis of transplanted tumors

alleviate lung injury and improve the drug resistance of A549/DDP to cisplatin

with a certain dose-effect relationship. High-dose concentration (5.84 g·kg

-1

) was the best concentration in nude mice.

关键词

Keywords

references

Bray F , Ferlay J , Soerjomataram I . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. CA Cancer J Clin , 2018 , 68 ( 6 ): 394 - 424 .

Nakamura H , Saji H . A worldwide trend of increasing primary adenocarcinoma of the lung [J]. Surg Today , 2014 , 44 ( 6 ): 1004 - 1012 .

WANG Q S , LIN X P . Lung cancer epidemiology in mainland China [J]. Chin J Clin Oncol , 2006 , 3 ( 4 ): 244 - 253 .

Mok T S , WU Y L , Thongprasert S , et al . Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma [J]. N Engl J Med , 2009 , 361 ( 10 ): 947 - 957 .

刘小菊，刘红云，王海娟，等．肺腺癌A549/DDP细胞多药耐药机制及中药逆转剂的研究进展 [J]．中国实验方剂学杂志， 2015 ， 21 ( 21 )： 227 - 230 ．

葛玲玲，曹芳．补中益气汤治疗肿瘤的现代应用 [J]．山东中医药大学学报， 2018 ， 42 ( 4 )： 367 - 369 ．

史妍婷，井欢，王莹，等．补中益气汤含药血清逆转A549/DDP的顺铂耐药及对mTOR表达的影响 [J]．中国实验方剂学杂志， 2013 ， 19 ( 9 )： 215 - 219 ．

唐莹．郭倩，于宁，等．补中益气汤含药血清对TGF-β1介导的A549细胞中Twistl表达的影响 [J]．中华中医药学刊， 2017 ， 35 ( 6 )： 1451 - 1453 ．

井欢，唐莹，于丹，等．补中益气汤含药血清同siRNA对A549/DDP细胞MRP表达影响的比较 [J]．中国实验方剂学杂志， 2014 ， 20 ( 8 )： 150 - 153 ．

高原，王莹，陈奇，等．补中益气汤对肺腺癌荷瘤裸鼠移植瘤的抑瘤作用及MRP蛋白表达影响的研究 [J]．时珍国医国药， 2016 ， 27 ( 8 )： 1796 - 1799 ．

Nasarre P , Gemmill R M , Potiron V A , et al . Neuropilin-2 is upregulated in lung cancer cells during TGF-β1 induced epithelial-mesenchymal transition [J]. Cancer Res , 2013 , 73 ( 23 ): 7111 - 7121 .

钟文昭，董嵩，李磊，等．国际肺癌研究协会/美国胸科学会/欧洲呼吸学会肺腺癌的国际多学科分类 [J]．循证医学， 2011 ， 11 ( 4 )： 193 - 225 ．

郑莉莉．补中益气汤逆转非小细胞肺癌多药耐药机制研究 [J]．云南中医学院学报， 2017 ， 40 ( 2 )： 98 - 102 ．

李杰，龚民，崔永，等．肺耐药蛋白LRP在肺癌中的表达及意义 [J]．现代肿瘤医学， 2014 ， 22 ( 12 )： 2875 - 2879 ．

FANG Q , REN G G , HAN Y T , et al . Multidrug resistance in primary tumors and metastases in patients with esophageal squamous cell carcinoma [J]. Pathol Oncol Res , 2013 , 19 ( 4 ): 641 - 648 .

段梅梅，付佳佳．外周血检测MRP与基质金属酶-9对肺癌患者化疗疗效的评估价值 [J]．现代医院， 2018 ， 18 ( 10 )： 1548 - 1550 ．

刘凯，王本军，马恒，等．补中益气汤对胃癌术后气虚血瘀证胃肠功能恢复和营养状况的影响 [J]．中国实验方剂学杂志， 2015 ， 21 ( 24 )： 152 - 156 ．

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Astragalus Polysaccharides Improve Cisplatin Resistance by Inhibiting EMT of Lung Adenocarcinoma A549/DDP Cells Transplanted into Nude Mice

Experimental Research on PI3K/AKT Expression Mechanisms of Buzhong Yiqi Decoction in Nude Mice Lung Adenocarcinoma Transplantation Tumor

Buzhong Yiqitang Regulates Endoplasmic Reticulum Stress to Attenuate Cisplatin Resistance in Non-small Cell Lung Cancer via Nrf2/ROS Pathway

Buzhong Yiqitang Induces Ferroptosis by Regulating PCBP1 to Attenuate Cisplatin Resistance in Non-small Cell Lung Cancer

Mechanism of Modified Si Junzitang and Shashen Maidong Tang in Improving Sensitivity of Cisplatin in EGFR-TKI Resistant Lung Adenocarcinoma Cells Based on Aerobic Glycolysis

Related Author

Ying ZHANG

Chun WANG

Dan YU

Yuan GAO

Huan JING

Ying WANG

LIU Ya-li

TANG Ying

Related Institution

Jining Medical University

College of Integrated Chinese and Western Medicine， Liaoning University of Traditional Chinese Medicine

Shenshan Medical Center， Sun Yat-sen Memorial Hospital of Sun Yat-sen University

Longhua Hospital，Shanghai University of Traditional Chinese Medicine

Longhua Hospital Shanghai University of Traditional Chinese Medicine

AI问答

Postal code：100700
Tel：010-84076882 Email：syfjx_2010@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备11006657号-10 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰